TEST:

ADXBLADDER

"Based on the results of this simulation, a marker-supported follow-up of patients with HR NMIBC is safe and offers the option to significantly reduce the number of WLCs. Further research focusing on prospective randomized trials is needed to finally find a way to implement urine markers into clinical decision-making."

P=N/A; Trial completion date: Oct 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Jan 2023

"Urinary biomarkers might have a complementary place in bladder cancer diagnosis and NMIBC surveillance. However, their clinical benefit remains to be confirmed."

P=N/A; N=650; Recruiting; Sponsor:Arquer Diagnostics Ltd

MCM5 has an overall moderate diagnostic accuracy for detecting BC. Subgroup analysis revealed good diagnostic performance in patients with high-grade tumors and primary diagnosis of symptomatic patients.

Patients with LG pTa tumor at the previous diagnosis, for which the risk of HG/CIS recurrence is low and the ADXBLADDER NPV for ruling out HG/CIS recurrence is 99.15%, are ideally suited for a less intensive, personalized follow-up surveillance strategy using ADXBLADDER, with omission of cystoscopy for ADXBLADDER-negative patients.

There is not enough data to reliably assess their use in the primary diagnostic setting. These results have to be confirmed in larger cohort as well as in head-to-head comparative studies.

"Our analyses support high diagnostic accuracy of the studied novel UBTs, supporting their utility in the NMIBC surveillance setting. All of these might potentially help prevent unnecessary cystoscopies safely. There are not enough data to reliably assess their use in the primary diagnostic setting. These results have to be confirmed in a larger cohort as well as in head-to-head comparative studies. Nevertheless, our study might help policymakers and stakeholders evaluate the clinical and social impact of the implementation of these tests into daily practice."

No abstracts available

No abstracts available